A patient treated with the NG101 antibody during occupational therapy.
Photo Credit: Universitätsklinik Balgrist
Scientific Frontline: Extended "At a Glance" Summary: Anti-Nogo-A Therapy (NG101)
The Core Concept: Anti-Nogo-A therapy utilizes a novel monoclonal antibody, NG101, to stimulate the regeneration of damaged spinal cord tissue. By neutralizing growth-inhibiting proteins in the central nervous system, it enables severed nerve pathways to re-establish functional connections.
Key Distinction/Mechanism: Unlike traditional rehabilitation that relies on compensatory mechanisms, NG101 acts causally by targeting and blocking the Nogo-A protein found in myelin sheaths. Removing this molecular barrier allows surviving and newly formed nerve fibers to physically grow across lesion sites and reconnect with brain and motor control centers.
Origin/History: The Nogo-A protein and its inhibitory effects on neurite growth were discovered at the University of Zurich roughly 30 years ago. Extensive trials culminated in a multinational clinical study completed in late 2024, with pivotal MRI results published in May 2026 demonstrating objective structural healing.
Major Frameworks/Components:
- Monoclonal Antibody NG101: An engineered therapeutic antibody designed specifically to neutralize Nogo-A within the central nervous system.
- Nogo-A Protein: A membrane protein present in the myelin sheaths of nerve fibers that actively blocks neurite outgrowth and tissue repair following an acute injury.
- Structural Neuroplasticity: The biological mechanism of forming new neural connections and physically rebuilding interrupted motor-nerve pathways.
- High-Resolution MRI Evaluation: Advanced imaging utilized to objectively visualize and quantify micro- and macrostructural changes in regenerating spinal cord tissue.
Branch of Science: Neuroscience, Neurobiology, and Clinical Neurology.
Future Application: This approach establishes a foundation for targeted biological treatments in acute complete and incomplete spinal cord injuries, with ongoing research exploring its efficacy in stroke recovery and other central nervous system traumas utilizing objective imaging for strategic intervention.
Why It Matters: By actively promoting the regrowth of severed nerve fibers, this therapy provides a direct biological intervention capable of restoring vital motor functions, such as arm and hand control, and significantly improving everyday independence for patients suffering from severe paralysis.
An international research group recently demonstrated that the antibody NG101 promotes the regeneration of damaged spinal cord tissue. Now, under the leadership of scientists at the University of Zurich and Balgrist University Hospital, the group has revealed for the first time how the therapy actually works. With a boost from this novel antibody, new nerve fibers form functional connections once again, allowing patients to become more independent.
Spinal cord injuries—often caused by sports or traffic accidents—can result in tetraplegia or paraplegia and severely limit independence. In late 2024, an international research group led by the University of Zurich (UZH) and Balgrist University Hospital completed a multinational clinical trial in which patients with acute spinal cord injuries were successfully treated with the novel antibody NG101. The results showed that NG101 accelerates the regression of spinal cord lesions and preserves existing nerve tissue.
Antibody Neutralizes Unhelpful Protein
Discovered at UZH roughly thirty years ago, NG101 targets the protein Nogo-A, which is found in the sheaths of nerve fibers in the spinal cord and brain. This protein blocks the healing of damaged nerve fibers in the spinal cord following acute injury. By neutralizing Nogo-A, NG101 removes this barrier to growth and healing, thereby boosting nerve fiber regeneration and supporting the functional regeneration of spinal cord tissue.
Visible Results in the Spinal Cord
The research team’s latest study has revealed another critical piece of the puzzle. “In our new study, we were able to use advanced imaging methods to show for the first time how this antibody therapy works directly in the spinal cord,” says Patrick Freund, UZH professor and head of the Spinal Cord Injury Center at Balgrist University Hospital.
The magnetic resonance imaging data revealed two important effects. First, spinal cord injuries healed more quickly in the presence of NG101, which suggests that nerve fibers were able to regenerate in the tissue surrounding the injury. Second, the loss of nerve tissue slowed down considerably and was offset by the regrowth of new nerve fibers. Previous animal experiments conducted by the researchers had already established how critical this stage is. This is because newly formed nerve fibers must navigate across or around the injury site to restore the pathways linking the brain and the spinal cord.
New Connections to Peripheral Nerves
The group’s latest findings suggest that NG101 supports precisely this process. “This allows surviving and newly regenerated nerve fibers to reestablish connections with the spinal cord centers that control the hand, arm, and leg nerves,” says Freund, who led the study. “These connections are essential for relaying signals from the brain to the muscles.” For some patients, this means a greater chance of recovering arm and hand function.
NG101 not only improves the function of the spinal cord but has also been shown to alter its structure, which supports the regeneration of nerve tissue. This marks an important step toward new, effective treatments for spinal cord injuries. “We are now able to visualize the effect of the therapy early on and in an objective way,” says Freund. “This opens up the possibility of using future treatments more strategically and conducting a more reliable evaluation of their outcomes.”
Published in journal: Nature Communications
Authors: Lynn Farner, Paulina S. Scheuren, Kiomars Sharifi, Tim M. Emmenegger, Maryam Seif, Michèle Hubli, Martin Schubert, Marc Bolliger, Rüdiger Rupp, Norbert Weidner, Rainer Abel, Doris Maier, Klaus Röhl, Michael Baumberger, Margret Hund-Georgiadis, Marion Saur, Jesús Benito, Kerstin Rehahn, Mirko Aach, Andreas Badke, Jiri Kriz, Tim Killeen, Alan J. Thompson, Nikolaus Weiskopf, Martin E. Schwab, Armin Curt, Patrick Freund, and the Nogo Inhibition in Spinal Cord Injury (NISCI) Study Group
Source/Credit: Universität Zürich
Reference Number: ns051226_01
.png)
.jpg)